Treatment Action Group (TAG) fiercely condemns the new presidential administration’s deadly and hateful attack on people living with HIV and their communities at home and around the world.
People living with or at risk of hepatitis C Virus (HCV), health care providers, and policymakers in low- and middle-income countries (LMICs) showed significant interest in a potential long-acting HCV cure, recent surveys have found.
Treatment Action Group (TAG) is appalled by President Donald Trump’s executive order Monday signaling the United States will be withdrawing from the World Health Organization (WHO).
TAG submitted this this input for the Office of the High Commissioner on Human Rights (OHCHR), in response to its request for "Inputs for the comprehensive report, incl. new developments, in ensuring access to medicines, vaccines and other health products."
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
TAG’s Cheat Sheets for Tuberculosis Activists are designed to help advocates navigate the range of tools in use and in the research pipeline.
To help advocates stay up to date, Treatment Action Group (TAG) organized a series of virtual trainings on the diagnosis, treatment, care and support of people with drug-resistant TB, designed for community and civil society organizations.
This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.
The 1/4/6x24 Campaign warns that regimens to treat drug-resistant TB recently recommended by World Health Organization (WHO) and important diagnostic tools will remain out of reach due to high prices.